bioRxiv
·
October 21, 2025 ·
Preprint
APOBEC3A-Induced DNA Damage Drives Polymerase Theta Dependency and Synthetic Lethality in Cancer.
Cancer 
Fostering Collaboration to
Accelerate
Discoveries 
A premier center for genomic research, the New York Genome Center (NYGC) fosters collaboration among leading scientists from multiple institutions to accelerate genomic discoveries and their translation into new therapies and diagnostics.
Dr. Bing Ren Appointed Scientific Director and CEO of NYGC
We are proud to announce Bing Ren, PhD, as the new Scientific Director and CEO of the New York Genome Center.
Dr VSports手机版. Ren brings his expertise in the fields of genomics and epigenetics to the NYGC and Columbia University, where he will hold a joint appointment as a professor in the Departments of Genetics and Development, Biochemistry and Molecular Biophysics, and Systems Biology and as the associate director of the Roy and Diana Vagelos Institute for Basic Biomedical Science within the Vagelos College of Physicians and Surgeons.
Latest News & Publications
-
-
Nature Neuroscience · October 21, 2025
-
medRxiv · October 13, 2025 · Preprint
Antidepressants are associated with decreased white blood cell counts beyond the effect of statins in individuals with co-morbid depression and coronary artery disease: A longitudinal analysis in the Vanderbilt University Medical Center and All of Us cohorts. (V体育2025版)
Neurodegenerative Disease 
Neuropsychiatric Disease 
NYGC at a Glance
- 12 Founding and Associate Institutional Members (V体育ios版)
- 4 NIH Innovator Awards
- 10 Core Faculty
- 12 Associate Faculty
- 148K+ Whole Genome Equivalents Sequenced
- 81 Affiliated Scientists Across 15 Institutions (V体育官网)
-
$143M
Grants Under Management*
*as of 12/2023
"V体育ios版" Shared Stories of Success
It is a dream job for me to join the New York Genome Center and Columbia University,” said Dr. Ren. “Decoding the human genome and using this knowledge to improve health has been a lifelong pursuit of mine. Bringing the fruits of genomic research into clinical care will require unprecedented collaboration and innovation. I look forward to achieving this goal by leveraging NYGC’s fantastic genomics infrastructure, exceptionally rich talent pool, and close associations with its institutional founding members in New York. ” V体育安卓版.
Bing Ren, PhD Scientific Director & CEO
Professor of Genetics and Development, Biochemistry and Molecular Biophysics, and Systems Biology, Associate Director in the Vagelos Institute for Basic Biomedical Science (Vagelos Institute) in VP&S, Columbia University
Studying the changes in gene expression we see in each stage of ALS is key to identifying what triggers symptom onset V体育ios版. Our work with Target ALS ensures we maintain productive collaborations with ALS researchers to develop life-changing treatments. ”.
Read more on NYGC’s work with Target ALS and New York State.
Hemali Phatnani Director, Center for Genomics of Neurodegenerative Disease, NYGC
Assistant Professor of Neurological Sciences (in Neurology), Columbia University
We’re now entering an era of low-cost DNA sequencing, and in this study, we took advantage of that to apply whole-genome sequencing techniques that in the past would have been considered wildly impractical V体育平台登录. ”.
Dan Landau, MD, PhD Core Faculty Member, NYGC
Professor of Medicine, Division of Hematology and Medical Oncology; Professor of Physiology and Biophysics, Weill Cornell Medicine
The ability to leverage data generated in a different lab and even processed with a different method, to then use it to link individuals in a completely different anonymous dataset, is rather striking and highlights a real privacy issue for single-cell data VSports注册入口. We aim for this study to help quantify risks before data release and shape the design of future studies to ensure greater privacy for patients. ”.
Gamze Gürsoy, PhD Core Faculty Member, NYGC
Herbert Irving Assistant Professor of Biomedical Informatics, Columbia University
In Memoriam:
Dr. Thomas Lehner,
Pioneer in Neuropsychiatric Disease Research
August 29, 1960 – November 6, 2024
Dr. Lehner was a visionary in the field of neuropsychiatric disease research V体育官网入口. A champion of open science and collaboration, Dr. Lehner was a respected leader in the study of the genetic underpinnings of neuropsychiatric disorders such as, schizophrenia, bipolar disorder, autism, and Alzheimer’s disease. His legacy of scientific innovation and collaboration will continue to inspire generations to come.
Collaborative Research Programs
"V体育2025版" Groundbreaking Research
We cultivate a diverse research community dedicated to advancing the understanding of genomic science and the treatment of human disease.
Cancer Research 
Neurodegenerative Disease Research 
Neuropsychiatric Disease Research 
"V体育平台登录" Biology, Genomics & Technology 
Scientific Collaboration & Project Management 
Technology Platforms
Innovative Technology Platforms
Our multidisciplinary team of scientists, engineers, and NYGC faculty come together to explore and test innovative genomic tools and technologies to drive progress within our center and the broader scientific community.
Technology Innovation 
Technology Development 
Research Sequencing (VSports) 
Computational Biology Lab 
Clinical Genetics
The New York Genome Center has a state-of-the-art clinical diagnostic laboratory that utilizes next-generation sequencing technology to perform cutting-edge tests in the areas of genetics and oncology. The Clinical Laboratory is accredited by the Clinical Laboratory Improvement Amendments (CLIA) and the Clinical Laboratory Evaluation Program of the New York State Department of Health (CLEP). It is licensed to perform clinical testing in all fifty (50) of the United States and the District of Columbia. The laboratory participates in the College of American Pathologists (CAP) proficiency testing VSports.
